Media headlines about Cepheid (NASDAQ:CPHD) have trended somewhat negative recently, Accern Sentiment Analysis reports. The research firm identifies negative and positive news coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Cepheid earned a daily sentiment score of -0.01 on Accern’s scale. Accern also gave media stories about the scientific and technical instruments company an impact score of 45.6677622012411 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
Cepheid (CPHD) remained flat at $$52.95 during trading on Wednesday. The company’s stock had a trading volume of 2,651,100 shares, compared to its average volume of 1,245,852. Cepheid has a one year low of $25.09 and a one year high of $53.91. The company has a debt-to-equity ratio of 0.76, a quick ratio of 3.24 and a current ratio of 4.30.
ILLEGAL ACTIVITY WARNING: This story was first reported by StockNewsTimes and is the property of of StockNewsTimes. If you are viewing this story on another publication, it was illegally stolen and reposted in violation of US & international copyright legislation. The correct version of this story can be read at https://stocknewstimes.com/2017/12/06/cepheid-cphd-given-media-impact-score-of-0-01.html.
Cepheid is a molecular diagnostics company. The Company develops, manufactures and markets fully-integrated systems for testing in the Clinical and Non-Clinical markets. The Company’s systems enable molecular testing for organisms and genetic-based diseases by automating otherwise complex manual laboratory procedures.
Receive News & Ratings for Cepheid Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cepheid and related companies with MarketBeat.com's FREE daily email newsletter.